Pharma BD Deal Intelligence
Pfizer paid $1.9B for two pipeline anti-infectives; wrote off $1.4B as IPR&D immediately, then dumped the flagship asset for $10M four years later — a textbook failed bolt-on.
Full analysis, sources & comparables →FierceBiotech framed the $1.9B deal as Pfizer plugging late-stage holes in its anti-infectives pipeline at a 74% premium - a deal-making theme of the mid-2000s.
C&EN reported analyst Jon Stephenson of Summer Street called dalbavancin 'the big winner' for MRSA potential and estimated combined 2009 sales near $375M, a…
Three years post-deal, Pfizer withdrew the dalbavancin NDA after regulatory feedback - validating skepticism that part of the Vicuron value depended on…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Pfizer agrees to acquire Vicuron at $29.10/share cash (~$1.9B); 74% premium. Anti-infectives focus - anidulafungin, dalbavancin. Closed Sept 14, 2005.
Pfizer paid $1.9B for two pipeline anti-infectives; wrote off $1.4B as IPR&D immediately, then dumped the flagship asset for $10M four years later — a textbook failed bolt-on.
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Pfizer Inc. / Vicuron Pharmaceuticals Inc. (this deal) | 2005 | $1.9B | 25 |
| Pfizer Inc. / BioNTech SE | 2020 | $748M | 100 |
| Pfizer Inc. / FoldRx Pharmaceuticals | 2010 | — | 99 |
| Pfizer Inc. / Medivation Inc. | 2016 | $14.0B | 86 |
| Pfizer Inc. / Wyeth | 2009 | $68.0B | 86 |
| Pfizer Inc. / Warner-Lambert Company | 2000 | $90.0B | 83 |
| Pfizer Inc. / Arvinas, Inc. | 2021 | $2.4B | 77 |
← Browse all deals · How we score deals
More: 2005 deals · Pfizer Inc. deals